https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-03-20 / Rev Mal Respir 2019 Mar;36(3):415-425
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-03-20 / Rev Mal Respir 2019 Mar;36(3):415-4252019-03-20 00:00:002019-03-20 00:00:00[Vaccines for the treatment of non-small cell lung cancer]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-03-05 / Cancers (Basel) 2019 Mar;11(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-03-05 / Cancers (Basel) 2019 Mar;11(3)2019-03-05 00:00:002019-03-05 00:00:00Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-03-03 / Br. J. Haematol. 2019 May;185(4):679-690
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-03-03 / Br. J. Haematol. 2019 May;185(4):679-6902019-03-03 00:00:002019-07-01 09:16:10Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-03-01 / J Clin Oncol 37, 2019 (suppl 8; abstr TPS10)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-03-01 / J Clin Oncol 37, 2019 (suppl 8; abstr TPS10)2019-03-01 00:00:002020-05-06 15:08:24Randomized phase II trial of patient-specific dendritic cell vaccines loaded with autologous tumor antigens versus autologous monocytes in patients with primary advanced ovarian cancer.
